Evidence map›Paper›PMID 34915748›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Determinants of Second Primary Cancer Type in Survivors of Virus-Related and Non-Virus-Related Cancer Living With HIV in the French Dat'AIDS Cohort.

Isabelle Poizot-Martin, Caroline Lions, Clotilde Allavena, Pierre Delobel, Anne Fresard, Sylvie Brégigeon, Teresa Rojas, Cyrille Delpierre, Alain Makinson, Dat’AIDS study group

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Isabelle Poizot-MartinAPHM, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, APHM Sainte-Marguerite, Service d'immuno-hématologie clinique, 128791Aix Marseille Univ, Marseille, France.ORCID https://orcid.org/0000-0002-5676-5411
Caroline LionsAPHM Sainte-Marguerite, Service d'immuno-hématologie clinique, 128791Aix Marseille Univ, Marseille, France.
Clotilde AllavenaService des maladies infectieuses et tropicales, 26922CHU Hôtel-Dieu, Nantes, France.
Pierre DelobelService des Maladies Infectieuses et Tropicales, INSERM, UMR1291, Université Toulouse III Paul Sabatier, 36760CHU de Toulouse, Toulouse, France.
Anne Fresarddépartement des Maladies Infectieuses et Tropicales, 26926Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France.
Sylvie BrégigeonAPHM Sainte-Marguerite, Service d'immuno-hématologie clinique, 128791Aix Marseille Univ, Marseille, France.
Teresa RojasAPHM Sainte-Marguerite, Service d'immuno-hématologie clinique, 128791Aix Marseille Univ, Marseille, France.ORCID https://orcid.org/0000-0003-1536-3675
Cyrille Delpierre36760CERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Alain MakinsonDépartement des Maladies Infectieuses et Tropicales, INSERM U1175/IRD UMI 233, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Dat’AIDS study group
Hôpital Sainte-Marguerite · FRInserm · FRUniversité Toulouse III - Paul Sabatier · FRCentre Hospitalier Universitaire de Saint-Étienne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPeople who survive after primary cancer are at an increased risk for subsequent primary cancers. We aimed to investigate the possible determinants of second primary cancer (SPC) in HIV-positive cancer survivors.

methodsThis was a multicenter retrospective study using longitudinal data from the French Dat'AIDS cohort. Subjects who developed at least 2 primary cancers were selected. Cancer cases were identified using ICD10 codes and distributed in 3 cancer categories: AIDS-defining cancer (ADC), virus-related non-ADC (VR-NADC), and virus-unrelated-NADC (VU-NADC). The possible determinants considered were the first primary cancer category, sex, age, HIV transmission route, duration of HIV infection follow-up, duration of ART exposure, nadir CD4

resultsAmong the 44642 patients in the Dat'AIDS cohort, 4855 were diagnosed with cancer between 1 December 1983 and 31 December 2015, of whom 444 (9.1%) developed at least 2 primary cancers: 130 ADCs, 85 VR-NADCs, and 229 VU-NADCs. A longer delay between the first primary cancer and the SPC was associated with an increased risk of occurrence of a VR-NADC rather than a secondary ADC. Having had a first primary VU-NADC, an older age, and a longer delay between the HIV diagnosis and the first primary cancer as well as between the first primary cancer and the SPC were associated with an increased risk of VU-NADC rather than ADC.

conclusionSPCs are now a major concern in HIV-positive cancer survivors justifying the development of monitoring strategies after a first cancer.

Indexed as

AdultAgedCancer SurvivorsFemaleFranceHIVHIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedNeoplasmsNeoplasms, Second PrimaryRetrospective StudiesAIDSassociated factorscancer survivorsHIVsecondary primary cancer

Identifiers

PMID34915748
PMCPMC8704188
OpenAlexW4200496694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.